-------------------------------- Training Manual March 2009

Global Hemophilia Market ----------------------------------------------------- 2015

View Report DetailsExecutive SummaryHemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major population suffering with hemophilia globally. The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.By combining SPSS Inc.s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

View Report DetailsHemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia market is divided into four segments. According to 2014 estimates, hemophilia A makes up the majority of the hemophilia market with % of market share whereas hemophilia B makes only % of the market share. Hemophilia with inhibitors has % share, at second position, while Von Willebrand Disease (VWD) has a small % share.The broader hemophilia market is estimated to have grown from US$... billion in 2011 to US$... billion in 2014, representing an average % growth rate over this period mainly due to increased use of prophylaxis in developed countries, as well as pharmaceutical companies expansion of markets into underserved countries. Globally, hemophilia A type accounts for % of hemophilic patients with patients followed by hemophilia B with patients as of 2014. Inhibitor segment accounts for % share with to patients.Hemophilia Patients by Type (2014)Global Hemophilia Market Value (2010-2014E)Hemophilia Market by Segments (2014E)Worldwide, the estimate of prophylactic use amongst the patient population was only 17%. The global hemophilia A (Factor VIII) market is worth nearly US$... billion according to 2014 estimates, of which recombinant therapies (rFVIII) represent over US$... billion of the market while plasma-derived factors represent the remaining share. The hemophilia A market is expected to reach US$... billion by 2016 at a CAGR of % over the period 2011 to 2016.Global FVIII estimates for unit demand growth over the period 2014-2016 of % per annum, is slightly elevated compared to % growth observed in the previous three years i.e. 2010 to 2012. As of 2014, the demand is million units. A key factor that could augment the demand growth outlook in hemophilia A, particularly in emerging markets is the increased use of prophylactic treatment. In 2012, thousand patients suffering from hemophilia A had been treated and the figure is estimated to have risen to thousand patients in 2014 depicting an increase of %. Moreover, the number of treated patients is likely to rise further in future as well.Hemophilia A Patients Treated Per Year Globally (2010-2017E)Global Demand for Factor VIII (2010-2016E)Global Hemophilia A Market Value (2011-2016E)The global hemophilia market is controlled by five major players: Baxter, Novo Nordisk, Pfizer, Bayer and CSL Behring.The global hemophilia B (Factor IX) market was nearly US$... billion market in 2014, approximately one-fourth the size of the hemophilia A market. The hemophilia B market is expected to reach US$... billion by 2016 at a CAGR of % over the period 2011 to 2016.The number of new market entrants in the rFVIII space will surpass the number of existing players and could displant the stronghold that Baxter currently has on % of the rFVIII market as of 2013. Bayers Kogenate and Pfizer makes up % and % of the market share as of 2013 respectively.The global hemophilia A market is dominated by Baxter (Advate) making up % of the market share followed by Bayer (Kogenate), with % of share as of 2014. Pfizer (Refacto) and CSL Behring (Helixate) make up % and % of the market share respectively in 2014, and the rest % of the market is plasma derived.Hemophilia A Market Share by Company (2014)Recombinant FVIII Market Share by Company (2013)Global Hemophilia B Market Value (2011-2016E)Novo Nordisk has a very strong and long-standing presence in the market with NovoSeven which targets hemophilia Factor VIII and Factor IX patients with inhibitors. Hemophilia is more likely to occur in males than females. This is because females have two X chromosomes while males have only one, so the defective gene is guaranteed to manifest in any male who carries it. Because females have two X chromosomes and hemophilia is rare, the chance of a female having two defective copies of the gene is very remote, so females are almost exclusively asymptomatic carriers of the disorder. The incidence rate is 1 in every 50,000 male births for hemophilia A and 1 in 20,000 male births in case of hemophilia B. The global male population increased from billion in 2010 to billion in 2014 at a CAGR of % and is estimated to increase to around billion by 2025.Since hemophilia is a rare disorder, this obviously limits the size of the market and the number of customers. Currently about 20,000 people have hemophilia in the US, about % of them have hemophilia A, and 3,000 to 4,000 have hemophilia B. About 400 US babies with hemophilia are born each year. According to 2014 estimates, US hemophilia A market is worth US$... billion and hemophilia B market is worth US$... billion. The sales per patient in case of hemophilia A and B is US$... and US$... respectively.The global hemophilia market increased from US$... billion in 2011 to US$... billion in 2014 showing an increase of %. This increase was mainly due to increasing male population, increasing hemophilia A patients treated per year globally and rising health expenditure per capita. The market is forecasted to reach US$... billion in 2015 showing a rise of % versus prior year. This continuous growth is also due to rising awareness among the people about the treatment and innovation in tools and techniques related with the hemophilia, in particular with greater adoption of prophylactic treatment. The global hemophilia treatment market is expected to grow at a CAGR of % for the period spanning 2014-2018.Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versaGlobal Male Population (2010-2014)Global Hemophilia Market Forecast (2014-2018F)Koncept AnalyticsCS-36, Second Floor, Ansal PlazaVaishali, Ghaziabad, U.P. 201010T. +91-120-4130959C: +91-9811715635 vikas@konceptanalytics.comContact Us:www.konceptanalytics.com

Vikas GuptaBD ManagerThese are abridged and sanitized sample pages from the comprehensive report on the Global Hemophilia Market . To know more about this report or for any customized research requirement, please contact the following: View Report Details